Publication:
Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study.

dc.contributor.authorDinç, HARİKA ÖYKÜ
dc.contributor.authorDemirci, Mehmet
dc.contributor.authorÖzdemir, Yusuf Emre
dc.contributor.authorSirekbasan, Serhat
dc.contributor.authorAktaş, Ayse Nur
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorTuyji Tok, Yeşim
dc.contributor.authorÖzbey, Doğukan
dc.contributor.authorAkçin, Rüveyda
dc.contributor.authorGareayaghi, Nesrin
dc.contributor.authorKuşkucu, Mert Ahmet
dc.contributor.authorMidilli, Kenan
dc.contributor.authorAygün, Gökhan
dc.contributor.authorSarıbaş, Suat
dc.contributor.authorKocazeybek, Bekir
dc.contributor.institutionauthorDİNÇ, HARİKA ÖYKÜ
dc.date.accessioned2022-05-05T20:59:20Z
dc.date.available2022-05-05T20:59:20Z
dc.date.issued2022-04-05T00:00:00Z
dc.description.abstractBackground: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections is vital to understanding the role of antibodies in preventing infection. Aims: To determine the quantitative IgG responses specific to the Spike-S1 (S1) receptor-binding domain (S1/RBD) region of the virus in serum samples taken between 4 weeks and 7 months after polymerase chain reaction (PCR) positivity in patients who are diagnosed with coronavirus disease-2019 (COVID-19). Study design: A longitudinal study. Methods: This study included 113 patients with a clinical and molecular diagnosis of COVID-19. The first and second serum samples were taken 1 and 7 months, respectively, after the PCR positivity. S1/RBD-specific IgG antibody response was assayed using anti-SARS-CoV- 2 QuantiVac ELISA (IgG) kit (Euroimmun, Lübeck, Germany). The neutralizing antibodies were investigated in 57 patients whose IgG test results were above the cut-off value. Results: In 57 patients with SARS-CoV-2 IgG, the anti-SARS-CoV-2 IgG quantitative antibody levels significantly decreased after 7 months (Z = −2.197, p = 0.028). A correlation was detected between the anti-SARS-CoV-2 IgG and nAb percent inhibition (IH%) levels detected in 1 month (rs = 0.496, p < 0.001), but without significant correlation in serum samples taken on 7 months. The nAb IH% levels of the first and second were compared for COVID-19 severity and revealed no statistical difference (p = 0.256). In the second serum sample, the nAb IH%s of patients with moderate COVID-19 showed a statistically significant difference from patients with mild COVID-19 (p = 0.018), but without significant differences between severe and moderate or mild COVID-19. Conclusion: SARS-CoV-2 quantitative IgG antibody titers are significantly reduced at long-term follow-up (> 6 months). Due to the limited information on seroconversion, comprehensive studies should be conducted for long-term follow-up of the immune response against SARS-CoV-2.
dc.identifier.doi10.4274/balkanmedj.galenos.2022.2021-8-131
dc.identifier.pubmed35378574
dc.identifier.scopus85131018883
dc.identifier.urihttp://hdl.handle.net/20.500.12645/30570
dc.identifier.wosWOS:000806079300002
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectNeutralizing antibody
dc.titleAnti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study.
dc.typeArticle
dspace.entity.typePublication
local.avesis.idea64c9e0-fdae-49e8-8efc-9f9a0cfe4504
local.publication.isinternational1
relation.isAuthorOfPublication6f44fd83-f5fa-4152-9576-c7c1d7ce6ad1
relation.isAuthorOfPublication.latestForDiscovery6f44fd83-f5fa-4152-9576-c7c1d7ce6ad1
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection A Longitudinal Study.pdf
Size:
548.2 KB
Format:
Adobe Portable Document Format
Description: